Introduction
============

The number of malformed fetuses further increases with the ever-changing living conditions, which significantly affects the family well-being and national population. Fetal abnormality is referred to as developmental defects in fetal intelligence development, morphology and physiology attributable to various adverse factors in the course of fetal growth and development ([@b1-etm-0-0-7568]). Among all abnormalities, the congenital microtia, a common facial defect with an incidence of 5/10,000, is early detected during the prenatal examination, which is crucial for ensuring fetal quality. The chromosome 10q26 of fibroblast growth factor receptor 2 (FGFR2) gene, which primarily encodes tyrosine kinases, exerts a great effect on the cell growth and development as well as angiogenesis, and is involved in embryogenesis, especially in the process of cartilage and bone formation. Previous studies have demonstrated that the polymorphism of FGFR2 gene is bound up with the long bone mineral density of Chinese people, but there are no reports on the role of FGFR2 in bone formation and remodeling in adults ([@b2-etm-0-0-7568],[@b3-etm-0-0-7568]). Therefore, this study places emphasis on exploring the association of the single-nucleotide polymorphism (SNP) of rs3135718 site in FGFR2 gene with congenital microtia.

Patients and methods
====================

### General data

A total of 193 patients treated in Maternity and Child Health Care of Zaozhuang (Zaozhuang, China) and meeting the diagnostic criteria for congenital microtia and diagnosed with the congenital microtia from January 2010 to October 2017 were randomly selected as observation group. Moreover, 150 normal healthy children with the same age from January 2010 to October 2017 were selected as the control group. There were 105 males and 88 females with an average age of 14.33±6.58 years in observation group, and 87 males and 63 females with an average age of 13.75±7.51 years in control group. The statistical difference between the two groups was in sex (P\<0.05), but not in age (P\>0.05).

The study was approved by the Ethics Committee of Maternity and Child Health Care of Zaozhuang. Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians.

### Sample collection

After 2 ml venous blood was collected from all subjects enrolled, it was anti-coagulated with ethylenediamine tetracetic acid, sub-packaged and stored at −80°C. The genomic deoxyribonucleic acid (DNA) was extracted using the TIANamp Genomic DNA kit (Tiangen Biotech Co., Ltd., Beijing, China) in accordance with the instructions of the kit, and stored in a refrigerator at −20°C for standby application.

Quantitative polymerase chain reaction (qPCR). The primers (synthesized by Shanghai Invitrogen Biotechnology Co., Ltd., Shanghai, China) were designed using the Primer Premier5.0 software according to the DNA sequences of human FGFR2 gene reported in the NCBI database, and the rs3135718 site in FGFR2 gene was typed via Taq-man PCR. The primer sequences are shown in [Table I](#tI-etm-0-0-7568){ref-type="table"}. The PCR system was 20 µl in total: A total of 50 ng genomic DNA, 1X PCR buffer, 3 mmol/l MgCl~2~, 4 mmol/l dNTPs, 5 pmol/l primers and 1 unit TaqDNA polymerase (Qiagen, Inc., Valencia, CA, USA), and it was loaded on a CFX96 instrument for amplification (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Parameters of qPCR amplification: 95°C for 30 sec, 58°C for 30 sec, 72°C for 30 sec, and then extension at 72°C for 7 min after 30 cycles. The experimental results were generated by the built-in software. Three repeated wells were set for each sample. The experimental results were analyzed using the 2^−ΔΔCq^ method ([@b4-etm-0-0-7568]). The DEPC-treated water was used as the negative control, and the positive plasmid containing this sequence as the positive control (synthesized by Shanghai Sangon Biotech Co., Ltd., Shanghai, China).

### Statistical analysis

The Hardy-Weinberg equilibrium test was performed for the genotype frequency of rs3135718 site in FGFR2 gene, and SPSS 20.0 (IBM Corp., Armonk, NY, USA) was used for processing. The difference in allele frequency between the observation and control group was analyzed using χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference. The associations of rs3135718 polymorphism with the risk and clinicopathological parameters of congenital microtia were assessed via the unconditional logistic regression odds ratio (OR) and confidence interval (CI).

Results
=======

### Results of SNP genotyping

As shown in [Fig. 1](#f1-etm-0-0-7568){ref-type="fig"}, a wild homozygous type (AA type) was near the FAM abscissa, a mutant homozygous type (GG type) was near the VIC ordinate, and a heterogeneous type (AG type) was near the 45° line.

Hardy-Weinberg equilibrium analysis of distribution of rs3135718 genotype in FGFR2 gene. As shown in [Table II](#tII-etm-0-0-7568){ref-type="table"}, the distribution of gene and genotype frequency of rs3135718 site in FGFR2 gene in control group were consistent with the Hardy-Weinberg equilibrium, indicating that the subjects in this study were representative of the population (P\>0.05).

### Distribution of genotypes and their influences on congenital microtia

As shown in [Table III](#tIII-etm-0-0-7568){ref-type="table"}, the influence of rs3135718 genotype (AG) on the prevalence of congenital microtia had no statistically significant difference between the observation group and control group (P\>0.05).

### Logistic regression analysis of association between genotypes and risk of fetal microtia

The GG and G genotypes in rs3135718 were closely related to fetal microtia (P\<0.05) ([Table IV](#tIV-etm-0-0-7568){ref-type="table"}).

### Analysis of association between distribution of rs3135718 genotype frequency and risk of congenital microtia in the sexes

The results revealed that the mutation of rs3135718-GG site was more correlated with the risk of microtia in male (P\<0.05), but not correlated with the risk of microtia in female (P\>0.05), which could explain why the risk of microtia was higher in male to a certain extent ([Table V](#tV-etm-0-0-7568){ref-type="table"}).

### Association between distribution of allele frequency and risk of microtia

The distribution of allele frequency in rs3135718 gene in observation group and control group was analyzed using χ^2^ test. The results confirmed that there was no statistically significant difference in the distribution of allele frequency in total population (P\>0.05), while the difference in distribution of allele frequency of rs3135718-G in male between the two groups was statistically significant (P\<0.05) ([Table VI](#tVI-etm-0-0-7568){ref-type="table"}).

Discussion
==========

Microtia is one of the most common manifestations of facial deformity with a high incidence ([@b4-etm-0-0-7568],[@b5-etm-0-0-7568]). It was reported that the prevalence of neonatal microtia is 0.84--17.5/10,000 in the world and 3.79/10,000 in Australia, and it is higher in South America (3.2/10, 000) than that in other regions ([@b6-etm-0-0-7568],[@b7-etm-0-0-7568]). However, its etiology is still unclear. It is currently believed that scuh a congenital defect is largely attributable to both genetic and environmental factors ([@b8-etm-0-0-7568],[@b9-etm-0-0-7568]). The congenital microtia is primarily characterized by the abnormalities in external and middle ears, conductive or mixed deafness, mostly accompanied by preauricular pit, preauricular tag or accessory auricles, and some patients may also suffer from cleft palate, facial nerve dysplasia and facial asymmetry ([@b10-etm-0-0-7568],[@b11-etm-0-0-7568]). The SNP may be one of the original causes of congenital deformity. Guizar-Vázquez *et al* first discovered patients with familial aggregation microtia in the 1870s ([@b12-etm-0-0-7568]). Additionally, numerous studies have proposed that microtia is an autosomal dominant genetic disorder ([@b13-etm-0-0-7568],[@b14-etm-0-0-7568]). Along with the advancement of technology and the development of the times, the DNA detection has been one of the essential means to diagnose autosomal dominant genetic disorder. SNP is the most abundant form of DNA variation in human genome ([@b15-etm-0-0-7568],[@b16-etm-0-0-7568]). FGFRs, which belong to the family of receptor tyrosine protein kinases and contain at least 22 exons, act primarily by binding between their receptors and fibroblast growth factors ([@b17-etm-0-0-7568],[@b18-etm-0-0-7568]). Genetic studies have found that FGFR plays a vital role in the growth and development of bone and cartilage ([@b19-etm-0-0-7568],[@b20-etm-0-0-7568]). This study was designed to investigate the association of rs3135718 site in FGFR2 gene SNP with congenital microtia.

In this study, the association between the polymorphism of rs3135718 gene in FGFRs and congenital microtia was investigated for the first time, and the genotype frequency distribution in the sexes and the association of the distribution of allele frequency with the risk of microtia were analyzed. The data analysis indicated that the distribution of genotypes was in line with the H-W equilibrium law, and the distribution of genotype frequency of rs3135718 polymorphism site in FGFRs in observation group and control group was statistically significant. Further stratification analysis in the sexes revealed that the polymorphism of rs3135718-G gene in FGFRs was related to the occurrence of congenital microtia. Due to a quite complicated etiology of congenital microtia and limited sample size in this experiment, the study results need further confirmation.

The influence of rs3135718 genotype (AG) on the prevalence of congenital microtia had no statistically significant difference between the observation group and control group (P\>0.05). The GG and G genotypes in rs3135718 were closely related to fetal microtia (P\<0.05). The results revealed that the rs3135718-GG mutation was more correlated with the risk of microtia in male (P\<0.05), but not correlated with the risk of microtia in female (P\>0.05). Moreover, there was a statistically significant difference in the distribution of rs3135718-G allele frequency in male between the groups (P\<0.05), which accounted for the high incidence of congenital microtia in male patients.

In conclusion, the rs3135718-G gene in FGFR2 has a certain association with the incidence of fetal microtia with high prevalence and risk.
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###### 

Primer sequences.

  SNP         Fragment amplification primers   Probe primers
  ----------- -------------------------------- ------------------------
  Rs3135718   F: 5′-CCTCCAACAGTTTAGCTTTC-3′    FAM-CAACCCAAGCATTTTTAA
              R: 5′-TGAGCAGAAGCAACGTGACC-3′    VIC-CAACCCGAGCATTTTTAA

F, forward; R, reverse.

###### 

Hardy-Weinberg equilibrium analysis of distribution of rs3135718 genotype in FGFR2 gene.

  Site              Genotype   Control group   Composition ratio (%)   χ^2^ value   P-value
  ----------------- ---------- --------------- ----------------------- ------------ ---------
  FGFR2 rs3135718   AA         78              52.0                                 
                    AG         61              40.7                    0.278        0.654
                    GG         11              7.33                                 

###### 

Distribution of genotype and allele frequency of rs3135718 site \[n (%)\].

  Genotype   Observation group (n=193)   Control group (n=150)   χ^2^ value   OR (95% CI)   95% CI         P-value
  ---------- --------------------------- ----------------------- ------------ ------------- -------------- ---------
  AA         62 (32.1)                   78 (52)                 0.145        1.562         0.512--3.016   0.012
  AG         68 (35.2)                   61 (40.7)               0.040        0.328         0.411--2.568   0.850
  GG         63 (32.6)                   11 (7.33)               0.230        1.957         0.604--1.516   0.050

OR, odds ratio; CI, confidence interval.

###### 

Correlation between genotypes and risk of fetal microtia,

  SNP         Genotype   Crude OR (95% CI)      P-value   Corrected OR (95% CI)   P-value
  ----------- ---------- ---------------------- --------- ----------------------- ---------
  rs3135718   AA         0.943 (0.749--1.186)   0.614     0.987 (0.783--1.243)    0.910
              GG         0.630 (0.434--0.914)   0.015     0.725 (0.497--1.057)    0.095
              AG         0.652 (0.461--0.923)   0.016     0.731 (0.514--1.039)    0.180
              A          0.838 (0.713--0.985)   0.032     0.893 (0.758--1.052)    0.177
              G          0.723 (0.686--0.875)   0.052     0.783 (0.652--1.112)    0.065

OR, odds ratio; CI, confidence interval.

###### 

Analysis of correlation between distribution of rs3135718 genotype frequency and risk of congenital microtia in the sexes.

  Site        Sex      Genotype   Observation group composition ratio (%)   Control group composition ratio (%)   χ^2^ value   P-value   OR      95% CI
  ----------- -------- ---------- ----------------------------------------- ------------------------------------- ------------ --------- ------- --------------
  rs3135718   Male     AA         54                                        44                                    0.218        0.756     1.000   
                                  51.43                                     50.57                                                                
                       GG         43                                        28                                    0.020        0.025     0.056   1.421--3.582
                                  40.95                                     26.7                                                                 
                       AG         6                                         4                                     0            0.956     1.312   0.451--4.238
                                  4.8                                       4.41                                                                 
              Female   AA         50                                        34                                    0.059        0.952     1.000   
                                  56.8                                      53.97                                                                
                       GG         31                                        23                                    0.040        0.85      0.924   0.401--2.128
                                  35.22                                     36.51                                                                
                       AG         6                                         5                                     0            1.00      0.85    0.185--3.901
                                  6.82                                      7.94                                                                 

OR, odds ratio; CI, confidence interval.

###### 

Correlation between distribution of allele frequency and risk of microtia.

  Site        Sex       Genotype   Observation group composition ratio (%)   Control group composition ratio (%)   χ^2^    P-value   OR       95% CI
  ----------- --------- ---------- ----------------------------------------- ------------------------------------- ------- --------- -------- --------------
  rs3135718   General   A          130                                       139                                   0.006   0.936     1.000    --
                                   67.36                                     92.67                                                            
                        G          131                                       72                                                      0.0486   1.682--2.451
                                   67.88                                     61.07                                                            
              Male      A          60                                        48                                    0.000   0.993     1.000    --
                                   31.09                                     32                                                               
                        G          49                                        32                                                      0.038    1.653--2.649
                                   25.39                                     21.3                                                             
              Female    A          56                                        39                                    0.068   0.795     1.000    --
                                   29.02                                     26                                                               
                        G          37                                        28                                                      0.858    0.487--1.734
                                   19.17                                     18.67                                                            

OR, odds ratio; CI, confidence interval.
